Research Radartracking 1,762 published studies · 471 human · 11 safety signals · 58 clinical trials · 44 cancer pages · updated Sep 2026Open the Research Map →

Atezolizumab

← All agents

Catalog entry human-reviewed · each study below is labeled with how it was published · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Get cited updates on Atezolizumab
A monthly email when the research changes — $10/mo. Manage follows
Follow Atezolizumab
Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
2 published studies tagged to this agent1 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?

Human trial / meta-analysis — Includes human trial or meta-analysis evidence.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Auto-discovered · not yet curatedatezolizumab
Educational only, not medical advice. OncoForge makes no claim that Atezolizumab treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

Auto-discovered from 1 recent study; not yet curated.

Research

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CancerHuman evidenceMechanismSafetyTrial
Advanced Endometrial Cancer11—1
Endometrial Carcinosarcoma11—1
Recurrent Endometrial Cancer11—1
Non Small Cell Lung Cancer—1—1

Reported figures

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
0
Meta-analysis
1
Systematic review
0
Randomized trial
0
Clinical trial
0
Observational
0
Case report
0
Review
1
Preclinical
0
Other
0
2 studies1 human1 review/other

Tracking 2 published studies of Atezolizumab: 1 in humans, 1 reviews/other.

Reported direction across studies: 1 positive, 1 mixed.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether Atezolizumab works.

Cancers named in these studies

advanced endometrial cancer (1)recurrent endometrial cancer (1)endometrial carcinosarcoma (1)non-small cell lung cancer (1)

Conflicting evidence

All studies

Meta-analysisTrialReported positiveModerate evidenceTier 4 · clinicaln = 2456

Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis

Cancer treatment reviews · Apr 2024 · meta-analysis of randomized controlled trials (first-line ICI + platinum-based chemotherapy vs chemotherapy alone)

AtezolizumabAvelumabDurvalumabDostarlimabPembrolizumabadvanced endometrial cancerrecurrent endometrial cancerendometrial carcinosarcoma

This meta-analysis pooled five randomized trials (2456 patients) comparing addition of anti-PD-1 or anti-PD-L1 agents to standard platinum-based chemotherapy versus chemotherapy alone as first-line treatment for advanced or recurrent endometrial cancer. Adding immune checkpoint inhibitors improved progression-free survival overall and especially in tumors with deficient mismatch repair (dMMR); in mismatch repair–proficient (pMMR) tumors a statistically significant PFS benefit was reported only with anti-PD-1 agents, not anti-PD-L1 agents. The analysis reports PFS outcomes; the impact on overall survival remains to be clarified.

Reported effects: included patients 2456, n=2456 · pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 · +5 more

Studied with: carboplatin-paclitaxel chemotherapy.

Key findings
  • Five randomized trials comprising 2456 patients (1308 received ICIs + chemotherapy and 1148 chemotherapy alone) were included.
  • Addition of ICIs to chemotherapy improved PFS in the overall population (pooled HR, 0.63; 95% CI, 0.52–0.76; P < .001).
  • In the dMMR subgroup the pooled PFS benefit was larger (pooled HR, 0.34; 95% CI, 0.27–0.44; P < .001).
  • In dMMR tumors benefit was seen with both PD-L1 and PD-1 inhibitors (pooled HRs 0.39, 95% CI 0.28–0.55 and 0.34, 95% CI 0.27–0.44, respectively; both P < .001).
  • In pMMR patients a statistically significant PFS benefit was observed only with anti-PD-1 agents (anti-PD-1: HR 0.64, 95% CI 0.46–0.90, P = .010) but not with anti-PD-L1 agents (anti-PD-L1: HR 0.87, 95% CI 0.73–1.03, P = .104).
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewTrialMixed resultsLimited evidenceTier 4 · clinical

Recent Advances in Adjuvant Therapy for Non-Small-Cell Lung Cancer

Tuberculosis and respiratory diseases · Jan 2024

AtezolizumabPembrolizumabnon-small cell lung cancer

This is a review summarizing recent advances in adjuvant targeted therapy and immunotherapy for early-stage non-small cell lung cancer. It notes recent approvals (osimertinib for EGFR-mutated tumors; atezolizumab and pembrolizumab for selected resectable NSCLC) and that many trials are ongoing. The review states that optimal adjuvant strategies remain unresolved.

Studied with: chemotherapy.

Key findings
  • Osimertinib has been approved as an adjuvant for epidermal growth factor receptor (EGFR)-mutated tumors.
  • Atezolizumab and pembrolizumab have been approved for selected patients with resectable NSCLC.
  • Numerous ongoing studies are evaluating targeted therapies and immunotherapy with or without chemotherapy in the adjuvant setting.
  • Several questions about optimal adjuvant treatment strategies remain unanswered.
Limitations: Review article summarizing existing literature rather than reporting new primary data.; Abstract does not describe review methods, search strategy, or inclusion/exclusion criteria.; Does not provide quantitative synthesis or resolve outstanding questions about optimal adjuvant strategies..

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

What changed recently

The latest additions to Atezolizumab's evidence base, and anything that's been retracted.

Recently added

Cancers where Atezolizumab reported positive results

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Human evidence

Advanced endometrial cancer1 positive1 human
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
Cited positive studies (1)
Recurrent endometrial cancer1 positive1 human
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
Cited positive studies (1)
Endometrial carcinosarcoma1 positive1 human
Limitations: Meta-analysis focused on progression-free survival (PFS); impact on overall survival (OS) is not reported and remains uncertain.; Subgroup analyses by dMMR/pMMR and by drug class (anti-PD-1 vs anti-PD-L1) are based on pooled trial-level data and may be limited by heterogeneity and lack of patient-level data.; Three of five trials included endometrial carcinosarcoma, which may affect generalizability to typical endometrial carcinoma populations.; The abstract does not report safety/toxicity or follow-up duration, limiting assessment of risks and long-term outcomes..
Cited positive studies (1)

Evidence at a glance: Atezolizumab by cancer

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

Advanced endometrial cancerHuman trial / meta-analysisReported positive1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 PMID 38422895 · hazard ratios 0.34–0.87 across 6 studies

Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis

Based on a single study.
Endometrial carcinosarcomaHuman trial / meta-analysisReported positive1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 PMID 38422895 · hazard ratios 0.34–0.87 across 6 studies

Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis

Based on a single study.
Recurrent endometrial cancerHuman trial / meta-analysisReported positive1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: pooled HR overall 0.63 [0.52–0.76], p <.001, n=2456 PMID 38422895 · hazard ratios 0.34–0.87 across 6 studies

Most authoritative study: Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis

Based on a single study.
Non-small cell lung cancerInsufficient evidenceMixed results

No primary experimental studies yet.

Most authoritative study: Recent Advances in Adjuvant Therapy for Non-Small-Cell Lung Cancer

No human studies yet · No numeric effect sizes reported · Based on a single study.

Clinical trials studying Atezolizumab

22 ongoing · 14 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.

Completed
3 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar